FIELD: medicine.
SUBSTANCE: method consists in semiquantitative determination of postvaccinal immunity to antigens of pertussis, diphtheria and tetanus. For this, the solid phase, which is a test strip made of a nitrocellulose membrane with a pore diameter of 0.45 mcm and size of 0.5×2 cm, are sensitized by application of diphtheria 3.5 μl at a concentration of 0.1 mg/ml and tetanus 3.5 μl with a concentration of 0.05 mg/ml of anatoxins, whole cell pertussis antigen 3.5 μl, 20 MOE, and 3,5 μl of mouse IgG solution at a concentration of 0.1 mg/ml as a positive control. After test strips drying, incubating with a blocking solution of PBST in the wells of a plate placed on a shaker in a thermostat at a temperature of 37°C for 60 min, the solid phase is washed three times for 5 minutes with PBST, incubated with the test serum samples and control serum samples for 30 minutes at 37°C. The antibodies contacted to the solid phase are washed and "developed" using a diagnosticum, which is a conjugate of carbon nanoparticles with streptococcus G protein diluted at 1/45 for 60 minutes. The result is evaluated using a program of scanned imagesr analysis after test strips scanning in an ordinary plate scanner. With an anti-tetanus and antidiphtheria antibody content of less than 0.1 IU/ml, an inadequate protection is estimated for which immunization is required. At 0.1-1.0 IU/ml - a sufficient level of protection, which requires a booster dose of vaccine, and at values greater than 1.0 IU/ml - a high level of protection, and immunization required in 5 years or more. The presence of the protective titer of anti-pertussis antibodies is evaluated by calculating the threshold value: X=0.128(A-B)+B, where X is the threshold value of optical density, A is the optical density of a strongly positive sample, B is the optical density of a weakly positive sample, and if the obtained value of sample optical density is above the threshold value, it contains a protective level of anti-pertussis antibodies.
EFFECT: application of this method allows to use a test system to quantify the presence of protective postvaccinal immunity to three infections: pertussis, diphtheria and tetanus, simultaneously.
2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINED HEPTAVALENT VACCINE | 2012 |
|
RU2705163C2 |
METHOD FOR PRODUCING MIXED VACCINE | 2002 |
|
RU2264226C2 |
MIXED VACCINE FOR IMMUNOPROPHYLAXIS OF WHOOPING COUGH, DIPHTHERIA, TETANUS AND VIRAL HEPATITIS B AND D | 2003 |
|
RU2233673C1 |
COMBINED VACCINE FOR PREVENTING PERTUSSIS, DIPHTHERIA, TETANUS | 2015 |
|
RU2596919C2 |
DIAGNOSTIC TECHNIQUE FOR POSTVACCINAL IMMUNITY TO DIPHTHERIA IN CHILDREN LIVING ON TERRITORY OF EXPOSURE TO HAZARDOUS CHEMICAL FACTORS | 2013 |
|
RU2524636C1 |
METHOD FOR SELECTING PERSONS TO VACCINATE THEM AGAINST DIPHTHERIA AND TETANUS INFECTION | 0 |
|
SU1720006A1 |
THE MIXED VACCINE, A METHOD OF SIMULTANEOUS MIXED VACCINATION AND A METHOD OF IMMUNOGENICITY INCREASE | 1993 |
|
RU2121365C1 |
MIXED VACCINE FOR IMMUNE PROPHYLAXIS OF VIRAL HEPATITIS B, TETANUS, DIPHTHERIA AND WHOOPING COUGH | 1998 |
|
RU2130778C1 |
METHOD FOR PREVENTION OF REDUCED POSTVACCINAL HUMORAL IMMUNITY TO DIPHTHERIA AND PERTUSSIS IN SCHOOLCHILDREN OF 7-12 YEARS OLD, ASSOCIATED WITH UNFAVOURABLE ENVIRONMENTAL FACTORS | 2024 |
|
RU2826768C1 |
COMBINED VACCINE TO PREVENT WHOOPING COUGH, DIPHTHERIA, TETANUS, HEPATITIS AND INFECTIONS CAUSED BY TYPE B HAEMOPHILUS INFLUENZAE | 2015 |
|
RU2626532C2 |
Authors
Dates
2017-07-31—Published
2016-04-12—Filed